PhaseBio Pharmaceuticals Inc expected to post a loss of 66  cents a share - Earnings Preview

PhaseBio Pharmaceuticals

14/05/2022 03:04

* PhaseBio Pharmaceuticals Inc  PHAS.OQ   PHAS.O  is
expected
to show a rise in quarterly revenue when it reports  results on
May 16 (estimated). 
    * The Malvern Pennsylvania-based  company is expected to
report
revenue of $2.334 million, according to the mean estimate from 5
analysts, based on Refinitiv data.  
    * ​Refinitiv's mean analyst estimate for PhaseBio
Pharmaceuticals
Inc is for a loss of 66 cents per share. For the same quarter
last year, the company reported a loss of 87 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for PhaseBio
Pharmaceuticals Inc is $15​, above​ its last closing price
of $1.03. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  -0.52       -0.59      -0.90     Missed  -53.6
 Sep. 30 2021  -0.63       -0.61      -0.66     Missed  -8.9
 Jun. 30 2021  -0.09       -0.46      -0.60     Missed  -30.4​
 Mar. 31 2021  -0.73       -0.73      -0.87     Missed  -18.6
 ​​Dec.        -0.67       -0.70      -1.03     Missed  -46.1
 31 2020                                                
 Sep. 30 2020  -0.78       -0.77      -0.86     Missed  -12.1​
 Jun. 30 2020  -0.53       -0.52      -0.98     Missed  -88.5
 Mar. 31 2020  -0.37       -0.37      -0.52     Missed  -42.3
 This summary was machine generated May 14 at 02:04 GMT.  All
figures in US dollars  unless otherwise stated